Literature DB >> 27468123

Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients.

Fábio Nasser Santos1, Marcelo Rocha Souza Cruz2, Rachel Riera3.   

Abstract

CLINICAL QUESTION: Do patients above 70 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination? BOTTOM LINE: For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27468123     DOI： 10.1001/jamaoncol.2016.2050

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


  2 in total

1.  Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients.

Authors:  Huan Ye; Meiqin Shao; Xiaohong Shi; Lifeng Wu; Bing Xu; Qiang Qu; Jian Qu
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379

2.  Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients.

Authors:  Hirotake Saito; Atsushi Ohta; Eisuke Abe; Motoki Kaidu; Miki Shioi; Toshimichi Nakano; Tomoya Oshikane; Kensuke Tanaka; Katsuya Maruyama; Naotaka Kushima; Satoshi Tanabe; Satoru Utsunomiya; Ryuta Sasamoto; Hidefumi Aoyama
Journal:  Clin Transl Radiat Oncol       Date:  2017-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.